'State-of-the-heart' of cardiac laminopathies

Area of Science:

• Cardiovascular Genetics
• Molecular Cardiology
• Nuclear Structure and Function

Background:

• Mutations in the LMNA gene, encoding nuclear A-type lamins, are a primary cause of inherited dilated cardiomyopathy.
• LMNA-related dilated cardiomyopathy with conduction disease (DCM-CD) is a severe and aggressive condition with poorly understood pathogenesis.
• Current treatment options for LMNA-DCM-CD are limited, highlighting the need for novel therapeutic strategies.

Purpose of the Study:

• To review recent advancements in understanding the cardiac pathophysiological roles of A-type lamins.
• To identify potential therapeutic targets for LMNA-related DCM-CD.
• To explore novel treatment interventions for this severe cardiac disease.

Main Methods:

• Review of recent scientific literature on LMNA gene mutations and DCM-CD.
• Analysis of findings from various mouse models to decipher pathomechanisms.
• Examination of signaling pathways implicated in LMNA-DCM-CD pathogenesis.

Main Results:

• Despite extensive research, clear genotype/phenotype correlations for LMNA mutations remain elusive.
• Mitogen-activated protein kinases (MAPK) and Akt/mTOR signaling pathways are identified as key early-activated pathways in LMNA-DCM-CD.
• Inhibition of these signaling pathways has demonstrated encouraging effects on cardiac progression in DCM-CD models.

Conclusions:

• Targeting the MAPK and Akt/mTOR pathways presents a promising therapeutic strategy for LMNA-DCM-CD.
• Development of potent and specific compounds for these pathways could offer a novel intervention for patients.
• Further research into these pathways may lead to effective treatments for this aggressive form of inherited cardiomyopathy.